DB:IM3

Stock Analysis Report

Executive Summary

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer.


Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Immunomedics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IM3's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

16.8%

IM3

8.1%

DE Biotechs

7.2%

DE Market


1 Year Return

-29.3%

IM3

-5.4%

DE Biotechs

-17.5%

DE Market

Return vs Industry: IM3 underperformed the German Biotechs industry which returned -1.2% over the past year.

Return vs Market: IM3 underperformed the German Market which returned -14.1% over the past year.


Shareholder returns

IM3IndustryMarket
7 Day16.8%8.1%7.2%
30 Day-19.5%-11.8%-22.3%
90 Day-39.6%-22.7%-26.1%
1 Year-29.3%-29.3%-5.2%-5.4%-14.9%-17.5%
3 Year91.6%91.6%17.6%16.3%-18.7%-25.7%
5 Year232.5%232.5%-5.1%-7.5%-17.8%-29.1%

Price Volatility Vs. Market

How volatile is Immunomedics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Immunomedics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: IM3 (€11.64) is trading below our estimate of fair value (€83.87)

Significantly Below Fair Value: IM3 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: IM3 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: IM3 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IM3's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IM3 is overvalued based on its PB Ratio (10.5x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Immunomedics forecast to perform in the next 1 to 3 years based on estimates from 12 analysts?

58.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: IM3 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IM3 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IM3 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IM3's revenue (50% per year) is forecast to grow faster than the German market (4% per year).

High Growth Revenue: IM3's revenue (50% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: IM3 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Immunomedics performed over the past 5 years?

-43.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IM3 is currently unprofitable.

Growing Profit Margin: IM3 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: IM3 is unprofitable, and losses have increased over the past 5 years at a rate of -43% per year.

Accelerating Growth: Unable to compare IM3's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IM3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: IM3 has a negative Return on Equity (-133.71%), as it is currently unprofitable.


Next Steps

Financial Health

How is Immunomedics's financial position?


Financial Position Analysis

Short Term Liabilities: IM3's short term assets ($638.7M) exceed its short term liabilities ($71.8M).

Long Term Liabilities: IM3's short term assets ($638.7M) exceed its long term liabilities ($332.7M).


Debt to Equity History and Analysis

Debt Level: IM3's debt to equity ratio (2.7%) is considered satisfactory.

Reducing Debt: IM3's debt to equity ratio has reduced from 6.7% to 2.7% over the past 5 years.


Balance Sheet

Inventory Level: IM3 has a low level of unsold assets or inventory.

Debt Coverage by Assets: IM3's debt is covered by short term assets (assets are 89.9x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: IM3 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if IM3 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Immunomedics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate IM3's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate IM3's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if IM3's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if IM3's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IM3's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Immunomedics has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Behzad Aghazadeh
Executive Chairmanno dataUS$50.00k0.0018% $45.9k
Usama Malik
CFO & Chief Business Officer1.58yrsUS$1.39mno data
Morris Rosenberg
Chief Technology Officer2.17yrsUS$2.44mno data
Jared Freedberg
General Counsel & Corporate Secretary1.5yrsUS$1.84mno data
Kurt J. Andrews
Chief Human Resources Officer1.5yrsUS$1.50mno data
Scott Canute
Executive Director3yrsUS$307.81k0.0018% $45.9k
Brendan Delaney
Chief Commercial Officer2.33yrsUS$971.41kno data
William Fricker
Principal Accounting Officer1.58yrsno datano data
Phyllis Parker
Director of Administrationno datano datano data
Chau Cheng
Senior Director of Investor Relationsno datano datano data

1.5yrs

Average Tenure

50.5yo

Average Age

Experienced Management: IM3's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Behzad Aghazadeh
Executive Chairmanno dataUS$50.00k0.0018% $45.9k
Scott Canute
Executive Director3yrsUS$307.81k0.0018% $45.9k
Peter Hutt
Independent Director3yrsUS$36.13k0.0018% $45.9k
Khalid Islam
Independent Director3yrsUS$48.63k0.0018% $45.9k
Barbara Duncan
Independent Director1yrno datano data
Charles Baum
Independent Director1.08yrsno datano data
Robert Azelby
Director0.083yrno datano data

2.0yrs

Average Tenure

58yo

Average Age

Experienced Board: IM3's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.4%.


Top Shareholders

Company Information

Immunomedics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Immunomedics, Inc.
  • Ticker: IM3
  • Exchange: DB
  • Founded: 1982
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$2.830b
  • Listing Market Cap: US$2.553b
  • Shares outstanding: 213.93m
  • Website: https://www.immunomedics.com

Number of Employees


Location

  • Immunomedics, Inc.
  • 300 The American Road
  • Morris Plains
  • New Jersey
  • 7950
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
IMMUNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDApr 1984
IM3DB (Deutsche Boerse AG)YesCommon StockDEEURApr 1984
0J9HLSE (London Stock Exchange)YesCommon StockGBUSDApr 1984
IM3BRSE (Berne Stock Exchange)YesCommon StockCHCHFApr 1984

Biography

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. The company also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. Immunomedics, Inc. has clinical collaboration with AstraZeneca and MedImmune, to evaluate Imfinzi, a human monoclonal antibody against PD-L1, with sacituzumab govitecan as a frontline treatment of patients with TNBC and urothelial cancer; collaboration agreement with The Bayer Group for the development of epratuzumab; clinical and preclinical collaborations with academic cancer institutions, identifying new cancer indications for sacituzumab govitecan and the biology of the Trop-2 antigen; and research collaboration with the Memorial Sloan Kettering Cancer Center to investigate Sacituzumab Govitecan and Labetuzumab Govitecan in preclinical cancer models. Immunomedics, Inc. has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/27 20:52
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.